Actavis Pharma's Testosterone Gel Recalled by FDA Over Container Seal Defects, Impacting U.S. Supply
Actavis Pharma, Inc. faces a Class III recall for 15,944 cartons of Testosterone Gel 1% due to defective container side-seals causing product leakage. This U.S. nationwide recall, initiated by Teva Pharmaceuticals USA, Inc., highlights critical quality control vulnerabilities in packaging integrity. Procurement and regulatory teams must scrutinize supplier quality systems and container closure integrity to mitigate supply chain disruptions and ensure patient safety.
FDA-Initiated Recall of Actavis Pharma's Testosterone Gel Due to Container Integrity Failure
The U.S. Food and Drug Administration (FDA) has classified an ongoing recall (D-0198-2026) for Testosterone Gel 1%, a CIII controlled substance, distributed by Actavis Pharma, Inc., based in Parsippany, NJ. This voluntary, firm-initiated recall by Teva Pharmaceuticals USA, Inc. targets 15,944 cartons of Lot #100068692, with an expiration date of April 30, 2027. The primary concern stems from a "Defective Container," specifically a side-seal flaw that permits product leakage. This defect directly compromises the sterility and dosage integrity of the topical Testosterone Gel, posing a risk to product quality and potentially patient safety. For procurement directors, this event signals an immediate need to assess the stability of their supply lines for Testosterone Gel. The recall of a substantial quantity—15,944 cartons—distributed nationwide across the U.S. could lead to localized shortages or increased demand on alternative suppliers. Regulatory affairs heads must review their internal quality control specifications for container closure systems, particularly for semi-solid and liquid formulations, to prevent similar vulnerabilities. Business development executives should monitor market dynamics closely, as such recalls can create opportunities for competitors with robust quality track records to capture market share.
Commercial and Supply Chain Implications of Testosterone Gel Recall
The recall of Testosterone Gel 1% (ANDA076737), a key androgen replacement therapy, carries significant commercial ramifications for the pharmaceutical supply chain. The affected product, identified by various National Drug Codes (NDCs) including 0591-2921, 0591-3216, and 0591-3217, and package NDCs such as 0591-3216-30 for the 30-unit-dose packets, is a human prescription drug administered topically. The manufacturing site is Actavis Laboratories, Inc., located in Salt Lake City, UT 84108, with distribution handled by Actavis Pharma, Inc. from Parsippany, NJ 07054. The defect in the side-seal of the 2.5-gram unit dose packets directly impacts product stability and efficacy, necessitating the removal of the affected lot from the market. Procurement teams must immediately identify any inventory of Lot #100068692 within their systems and initiate quarantine procedures, coordinating with Teva Pharmaceuticals USA, Inc. for return or destruction. This event underscores the critical importance of rigorous incoming material inspection and vendor qualification programs that extend beyond API to packaging components. Supply chain VPs should evaluate their resilience strategies, identifying potential alternative sources for Testosterone Gel or similar androgen therapies to mitigate future disruptions. Business development executives should assess the competitive landscape, as this recall may shift market preferences towards products with demonstrated packaging integrity and consistent supply.
Broader Regulatory Scrutiny and Quality Assurance Imperatives
This Class III recall, initiated voluntarily by Teva Pharmaceuticals USA, Inc. and communicated via letter, serves as a critical reminder of the FDA's unyielding focus on product quality and manufacturing compliance. While a Class III classification indicates that exposure to the product is not likely to cause adverse health consequences, it still represents a deviation from current Good Manufacturing Practices (cGMP) and regulatory standards. The underlying issue of a defective container side-seal points to potential systemic weaknesses in packaging design, material quality, or manufacturing process controls at the production facility, Actavis Laboratories, Inc. Regulatory affairs heads should leverage this incident to conduct an internal audit of their own product portfolios, specifically examining container closure integrity test methods and validation protocols for all topical and sterile products. The broader regulatory environment, as evidenced by recent parallel events such as the FDA Class II Recall for Essential Wellness Pharma's Progesterone Injection due to sterility failures and the FDA hearing concerning Amgen's Tavneos market future, demonstrates a heightened scrutiny across various therapeutic areas. This necessitates a proactive approach to quality assurance, ensuring that all aspects of product manufacturing and packaging meet stringent regulatory expectations to avoid costly recalls, protect brand reputation, and maintain uninterrupted market supply.